Title : Improving delivery of hydrophobic bioactive molecules: A water-solubility strategy with preclinical proof of concept
Abstract:
Background: Poor aqueous solubility remains a major challenge in drug development and can restrict formulation options, bioavailability, tissue exposure, and therapeutic performance. Strategies that improve aqueous compatibility may help overcome these limitations and enable more effective delivery of hydrophobic bioactive molecules. At Trait Biosciences, we investigated whether improved water solubility can translate into improved pharmacokinetic (PK) properties, tissue delivery, and biological activity in preclinical models.
Methods: Starting with a hydrophobic active (cannabidiol [CBD]), we developed IP-protected scientific procedures to create hydrophilic derivatives, designed to improve aqueous solubility, PK performance, tissue distribution, and biological activity. Trait-led, characterized, and scaled-up molecules include CBD82S and CBD45L, which we evaluated across different routes of administration for systemic stability, tissue permeation, PK characteristics, and preclinical pain models. Additionally, gene-expression analysis was used to assess inflammatory responses in relevant tissues.
Results: Preclinical studies demonstrated that representative water-soluble molecules achieved systemic exposure and distribution into peripheral and central tissues compared with their hydrophobic parent molecules. Compared with the corresponding hydrophobic parent molecule, it showed improved distribution into biologically relevant tissues, supporting the potential of increased aqueous compatibility to enhance tissue delivery. These distribution findings were accompanied by biologically relevant activity. CBD82S demonstrated activity following topical administration in a pain model, with increased anti-inflammatory IL-10 and reduced pro-inflammatory IL-1β expression in pain-affected tissue. In a separate systemic pain model, inflammatory responses were also modulated in brain tissue, with CBD45L demonstrating pronounced suppression of IL-1β. Together, the PK, tissue-distribution, and gene-expression findings provide evidence that improved aqueous compatibility can support broader tissue delivery while retaining pharmacological activity.
Conclusions: Improving water solubility represents a promising strategy for addressing formulation and delivery challenges associated with hydrophobic bioactive molecules. Combining aqueous compatibility with favorable PK and tissue exposure while retaining biological activity may improve drug delivery and therefore therapeutic performance. These preclinical findings provide proof of concept for a broader approach that may be applicable to hydrophobic compounds across neurological, pain-associated, inflammatory, and other therapeutic applications.
